Analysts Update Their Price Forecasts For Zentalis Pharmaceuticals Inc. (ZNTL)

Fidelity Management & Research Co has recently announced that it has increased stake in Zentalis Pharmaceuticals Inc. (NASDAQ:ZNTL) by 13.15%. After grabbing 8.46 million shares, the institutional investor is now in possession of 0.98 million shares of the Healthcare Company. The new investment brought the stake of investor firm to 14.23% having worth around $186.32 million. Moreover, The Vanguard Group, Inc. increased its share by 79363.0 to have a control over 4.12 million shares. And Eventide Asset Management LLC raised its holdings to 1.07 million shares by acquiring 3.23 million shares or 5.43% of the stake.

Zentalis Pharmaceuticals Inc. (ZNTL) concluded trading on 05/24/23 at a closing price of $26.60, with 1.31 million shares of worth about $34.95 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 25.95% during that period and on Wednesday the price saw a loss of about -0.52%. Currently the company’s common shares owned by public are about 58.13M shares, out of which, 52.72M shares are available for trading.

A deeper look into what the analysts at Wall Street are thinking about the price target of this stock provides us with the following: 11 analysts are covering the ZNTL stock and their offered price forecasts bring an average price target of $45.90. Over the next 12 months, analysts forecasted that the stock’s price could jump as high as $70.00 and could fall to a lowest price of $27.00. The stock’s current price level is 42.05% above of average price target set by the analysts, while a rise to estimated low would result in gain of 1.48% for the stock. However, touching the estimated high of $70.00 would mean a gain of 62.0% for the stock.

According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 45 times over the past 12 months. They bought 1,103,165 shares in 14 of the transactions. In 31 selling transactions, insiders dumped 224,865 shares.

American Funds Small Cap World Fu, Eventide Healthcare & Life Scienc, and SPDR S&P Biotech ETF are the top 3 mutual funds which are holding stakes in Zentalis Pharmaceuticals Inc. American Funds Small Cap World Fu is currently holding 3.81 million shares of worth totaling $83.95 million. The company recently came buying 79576.0 shares which brought its stake up to 6.41% of the company’s outstanding shares. Eventide Healthcare & Life Scienc bought 0.3 million shares, after which its hold over company’s outstanding shares expand to 3.63%, leaving 2.16 million shares with the mutual fund that have a worth of about $47.51 million. SPDR S&P Biotech ETF, after buying 1.8 million shares, have now control over 3.03% of the stake in the company. It holds 31515.0 shares of worth $39.65 million.

Zentalis Pharmaceuticals Inc. (NASDAQ: ZNTL) started trading at $26.49, below -$0.25 from concluding price of the previous day. However, the stock later moved at a day high price of 26.83, or with a loss of -0.52%. Stock saw a price change of -0.04% in past 5 days and over the past one month there was a price change of 22.07%. Year-to-date (YTD), ZNTL shares are showing a performance of 32.08% which increased to 24.18% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $15.55 but also hit the highest price of $32.34 during that period. The average intraday trading volume for Zentalis Pharmaceuticals Inc. shares is 664.04K. The stock is currently trading 9.60% above its 20-day simple moving average (SMA20), while that difference is up 27.99% for SMA50 and it goes to 20.59% higher than SMA200.

Fidelity Management & Research Co acquired 8.46 million shares of Zentalis Pharmaceuticals Inc. having value of about $186.32 million. Data submitted at the U.S SEC by Fidelity Management & Research Co revealed that the firm now holds 0.98 million shares in the company valued at close to $26144475.0, or have control over 13.15% stake in the company. Zentalis Pharmaceuticals Inc. (NASDAQ: ZNTL) currently have 58.13M outstanding shares and institutions hold larger chunk of about 109.09% of that. Holding of mutual funds in the company is about 49.59% while other institutional holders and individual stake holders have control over 57.21% and 16.67% of the stake respectively.

The stock has a current market capitalization of $1.60B. It has posted earnings per share of -$4.31 in the same period. It has Quick Ratio of 8.00 while making debt-to-equity ratio of 0.00. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ZNTL, volatility over the week remained 5.15% while standing at 6.51% over the month.

Analysts are in expectations that Zentalis Pharmaceuticals Inc. (ZNTL) stock would likely to be making an EPS of -$1.04 in the current quarter, while forecast for next quarter EPS is -$1.05 and it is -$4.4 for next year. For the current quarter EPS, analysts have given the company a lowest target -$1.15 which is -$0.91 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -$1.34 in the same quarter a year ago. Stock’s fiscal year EPS is expected to drop by -20.50% while it is estimated to decrease by -2.30% in next year.

Analysts at 11 brokerage firms have issued recommendations for the Zentalis Pharmaceuticals Inc. (ZNTL)’s stock and average of those rates the stock at a “Strong Buy” and assign it a score of 1.50. Out of those 11 Wall Street analysts, 11 recommended a “Buy” rating, while 0 were in favor recommending the stock as a “Hold” and 0 analyst recommended the stock as “Sell”.